Related Party Transactions (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended		6 Months Ended		9 Months Ended	12 Months Ended
	Jul. 12, 2024	Jan. 31, 2026	Mar. 26, 2025	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025	Dec. 31, 2025
Upfront payment	$ 2,500,000
Amendment fees	$ 500,000
Advisory fee expense			$ 11,328,565	$ 3,586,575		$ 4,946,575
Advisory fee paid			$ 2,500,000
Monthly installments								$ 7,071,424
Payment of outstanding accrued advisory fee		$ 1,757,141
Diluted shares outstanding				24,663,745	19,026,776	23,984,419	18,589,859		22,000,000.0
Advisory fee									$ 4,546,575
Accrued advisory fee related party				$ 1,656,575		$ 1,656,575		1,757,141	1,757,141
Nasdaq listing fee							$ 11,328,565
Reimbursable expenses						55,933
Reimbursable expenses payable				351,302		351,302
Annual patent maintenance fee						$ 20,000
Royalties percentage						4.00%
Utilizes laboratory and patent maintenance services				0	$ 82,225	$ 38,409	184,449
Accrued laboratory and patent maintenance fees payable				361,535		361,535		361,535	361,535
Outstanding amounts payable to USC for clinical trial services				1,135		1,135		283,250	283,250
Subcontract payable to USC				435,655		435,655
Accrued compensation				255,099		255,099		$ 255,099	$ 255,099
Research and development expenses [Member]
Utilizes laboratory and patent maintenance services				0	82,225	0	164,449
General and administrative expenses [Member]
Utilizes laboratory and patent maintenance services				$ 0	$ 0	$ 38,409
Laboratory And Patent Maintenance Services [Member]
Utilizes laboratory and patent maintenance services							$ 20,000